Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Infinity Pharmaceuticals

  • Adelene Perkins, Infinity Pharamaceuticals

We are an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. We are focusing our efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma or PI3K-gamma.

  • Date:Monday, February 11
  • Time:10:00 AM - 10:15 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submitting Company:Infinity Pharmaceuticals
  • Submission ID:23316
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Communicate IPI-549 and Infinity to a broader audience.
  • Company Website:infi.com
  • Company HQ City:Cambridge
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Ticker:INFI
  • Exchange:Nasdaq
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:IPI-549
  • Development Phase of Primary Product:Phase I
Speakers
Adelene Perkins
Infinity Pharamaceuticals
Back